7 Best Alternatives to AstraZeneca AI in 2026

Why look beyond AstraZeneca AI

AstraZeneca's application of AI is primarily an internal strategic initiative focused on enhancing its pharmaceutical research and development capabilities. While effective for its specific corporate objectives, this approach means AstraZeneca AI is not a commercial product or service available for external use. Organizations seeking to integrate AI into their drug discovery, development, or broader life sciences workflows will find that AstraZeneca does not offer public APIs, SDKs, or managed platforms for external developers or researchers [source]. Therefore, companies, academic institutions, or startups aiming to leverage AI for similar purposes must look to third-party providers that offer accessible, scalable, and customizable AI solutions. These alternatives often provide specialized models, data integration capabilities, and computational infrastructure designed for the unique challenges of drug discovery, target identification, and clinical research, catering to a diverse range of operational scales and technical requirements.

Top alternatives ranked

1. 1. Recursion Pharmaceuticals — Accelerating drug discovery through industrial-scale experimental biology and computational methods

   Recursion Pharmaceuticals integrates experimental biology with machine learning to map human biology and accelerate drug discovery. Their Recursion OS platform combines automated wet-lab experimentation with a proprietary inference engine to generate and analyze biological data at scale. This approach allows for the identification of novel drug candidates and targets across various disease areas [source]. Recursion's methodology differs from traditional drug discovery by systematically perturbing biological systems and using AI to interpret the resulting phenotypic changes, aiming to reduce the time and cost associated with bringing new therapies to market.

   Best for: High-throughput phenotypic screening, novel target identification, drug repurposing, and accelerating preclinical drug discovery pipelines.

2. 2. BenevolentAI — AI-driven drug discovery and development for complex diseases

   BenevolentAI utilizes its AI platform to generate insights from biomedical data, aiding in the identification of novel drug targets, understanding disease mechanisms, and progressing drug candidates. Their platform integrates various data types, including scientific literature, clinical trial data, and proprietary experimental results, to create a comprehensive knowledge graph. This graph is then analyzed by machine learning algorithms to uncover previously unknown relationships and hypotheses relevant to drug discovery [source]. BenevolentAI focuses on transforming the drug discovery process from target identification through to clinical development, with an emphasis on addressing unmet medical needs in areas like neuroscience and immunology.

   Best for: Target identification, drug repurposing, disease mechanism elucidation, and accelerating early-stage drug development.

3. 3. Exscientia — AI-driven precision drug design and development

   Exscientia is a pharmaceutical AI company specializing in designing novel molecules from scratch using advanced AI algorithms. Their platform automates and optimizes various stages of drug discovery, from target validation to lead optimization and candidate selection. By integrating AI into the design process, Exscientia aims to generate drug candidates with specific properties more rapidly and efficiently than traditional methods [source]. They focus on creating highly optimized small molecules that have a higher probability of success in clinical trials, thereby reducing the overall cost and time of drug development.

   Best for: De novo drug design, lead optimization, accelerating candidate selection, and improving the success rates of drug development programs.

4. 4. DeepMind — Advancing scientific discovery and general AI capabilities

   DeepMind, a Google-owned AI research lab, focuses on developing advanced AI systems capable of solving complex problems. While not exclusively a drug discovery company, DeepMind's foundational research in areas like protein folding with AlphaFold has profound implications for pharmaceutical research [source]. Their work on general AI, reinforcement learning, and neural networks provides powerful tools and methodologies that can be adapted for various scientific discovery challenges, including understanding biological systems, predicting molecular interactions, and optimizing experimental design. Organizations can leverage DeepMind's open-source contributions and research insights to build their own specialized AI applications in drug discovery.

   Best for: Foundational AI research, protein structure prediction, complex scientific problem-solving, and developing novel AI methodologies for biological applications.

5. 5. Google AI — Comprehensive AI tools and infrastructure for diverse applications

   Google AI encompasses a broad array of AI research, tools, and platforms, including TensorFlow, Google Cloud AI, and specialized models. For drug discovery, Google AI offers scalable infrastructure for data storage and processing, machine learning frameworks for model development, and pre-trained models that can be fine-tuned for specific biological tasks [source]. Researchers and companies can leverage Google Cloud's powerful compute resources, MLOps tools, and data analytics services to build, train, and deploy custom AI solutions for target identification, compound screening, clinical trial optimization, and real-world evidence analysis. Google's extensive ecosystem supports a wide range of AI applications beyond drug discovery, offering flexibility and scalability.

   Best for: Large-scale machine learning research, custom model training and deployment, integrating advanced AI models into applications, and leveraging scalable cloud infrastructure for biological data analysis.

6. 6. Azure OpenAI Service — Secure and scalable integration of OpenAI models for enterprise

   Azure OpenAI Service provides access to OpenAI's powerful language models, including GPT-3, GPT-4, and DALL-E, within the secure and compliant environment of Microsoft Azure. For drug discovery, this service can be utilized for tasks such as analyzing vast amounts of scientific literature, generating hypotheses from research papers, summarizing clinical trial results, and developing intelligent chatbots for researcher support [source]. The enterprise-grade security, data privacy, and compliance features of Azure make it suitable for handling sensitive biomedical data, while the scalability of the Azure platform supports large-scale text analysis and knowledge extraction crucial for pharmaceutical R&D.

   Best for: Integrating large language models into enterprise applications, secure AI solution development within a cloud environment, scientific literature analysis, and generating insights from unstructured biomedical text data.

7. 7. OpenAI Enterprise — Custom, high-volume AI deployments with enhanced security

   OpenAI Enterprise offers a dedicated version of OpenAI's models designed for large-scale corporate deployments, providing enhanced security, privacy, and performance guarantees. This includes higher rate limits, longer context windows, and the ability to fine-tune models on proprietary data with guaranteed data isolation [source]. For pharmaceutical companies, this translates to the ability to process and analyze massive, sensitive internal datasets for drug discovery, clinical research, and R&D operations, without concerns about data leakage or shared infrastructure. OpenAI Enterprise supports complex reasoning tasks, advanced data synthesis, and the development of highly customized AI agents for specialized scientific applications.

   Best for: Large-scale enterprise AI deployments, custom model training and fine-tuning with proprietary data, enhanced data privacy and security needs, and high-volume API access for complex scientific applications.

Side-by-side

How to pick

Choosing an alternative to AstraZeneca AI requires evaluating your organization's specific needs in drug discovery and development, considering factors such as your internal capabilities, data infrastructure, and strategic goals. Since AstraZeneca AI is an internal program, external entities must seek commercial or partnership-based solutions.

• For high-throughput experimental biology and phenotypic screening: If your focus is on generating vast amounts of biological data and using AI to interpret complex cellular responses, Recursion Pharmaceuticals offers an integrated platform that combines automated wet-lab experimentation with machine learning for comprehensive biological mapping.
• For novel target identification and disease mechanism elucidation: If your primary goal is to discover new drug targets and gain deeper insights into disease pathways from diverse biomedical data, BenevolentAI's knowledge graph and AI inference engine are designed to uncover non-obvious relationships and generate testable hypotheses.
• For precision drug design and lead optimization: When the emphasis is on designing novel molecules with specific desired properties and accelerating the lead optimization phase, Exscientia's AI-driven drug design platform provides capabilities for generating highly optimized drug candidates.
• For fundamental AI research and complex scientific problem-solving: If your organization has strong internal AI capabilities and seeks to apply cutting-edge research to challenging biological problems, leveraging insights and open-source contributions from DeepMind can provide advanced methodologies, particularly in areas like protein structure prediction and general AI applications.
• For broad AI tools and scalable cloud infrastructure: For organizations requiring flexible AI development environments, scalable compute resources, and a wide array of machine learning tools to build custom solutions across various R&D stages, Google AI (especially through Google Cloud AI) offers a comprehensive ecosystem.
• For secure integration of large language models in enterprise: If your need involves leveraging the power of advanced language models for tasks like scientific literature analysis, hypothesis generation, or clinical trial documentation within a secure and compliant cloud environment, Azure OpenAI Service provides enterprise-grade access to OpenAI's models.
• For custom, high-volume large language model deployments with enhanced security: For large pharmaceutical companies requiring dedicated, highly secure, and customizable large language model instances for sensitive data analysis, proprietary model fine-tuning, and high-volume API usage, OpenAI Enterprise offers a tailored solution with increased privacy and performance guarantees.

Consider your budget, the level of integration required with existing systems, and the regulatory compliance needs when making your selection. Many of these alternatives operate on a partnership or custom enterprise pricing model, reflecting the specialized nature of drug discovery AI solutions.